Role of miRNA-27a and miRNA-224 in posttranscriptional regulation of PCSK9 gene in Iraqi patient with coronary artery disease

Abstract

AimThe aim of this study was to assess miRNA-27a and miRNA-224 expression levels in the blood samples from CAD patients and their role in the regulation of Proprotein Convertase Subtilisin/Kexin Type 9 Gene (PCSK9) expression. MethodsThis case-control study included (150) participants ranged in age from 30 to 65 years old, both male and female. Patients with atherosclerosis (n = 100) were chosen based on the clinical appearance of atherosclerotic coronary artery disease (ASCAD), as well as a medical and physical examination and documentation via coronary angiography, while the healthy group (n = 50) were chosen at random, and the health questionnaire and clinical examination revealed no signs of cardiovascular disease (CVD). For estimation of the expression levels of PCSK9, MiRNA-27a, and MiRNA-224 genes utilize reverse transcription-quantitative polymerase chain reaction (qRT-PCR) method was used. ResultsA current study found miRNA-27a gene expression level was 5.01 ± 0.75 in the ASCAD patients group based on 2-∆∆Ct and 1.00 ± 0.58 in the healthy control group, while miRNA-224 gene expression level of two study groups was 0.31 ± 0.15 vs 1.00 ± 0.58. In addition, analysis of PCSK9 expression level indicated that was 6.06 ± 1.84 in patient group and 1.00 ± 0.19 in healthy control group. ConclusionsThe fact that miRNA-27a and PCSK9 gene expression levels increased while miRNA-224 gene expression levels decreased indicated they have opposite activity in the development of CAD.